DRTS (Alpha Tau Medical) Research & Development: $35.87 Mil (TTM As of Mar. 2026)


DRTS Alpha Tau Medical Ltd DRTS
32 GF Score
Price $13.22
! 3 Warning Signs
View Full Analysis

What is Alpha Tau Medical Research & Development?

Alpha Tau Medical DRTS +4.67% 32 Research & Development is $35.87 Mil as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alpha Tau Medical's Research & Development for the three months ended in Mar. 2026 was $10.98 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $35.87 Mil.

Alpha Tau Medical  (NAS:DRTS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alpha Tau Medical Research & Development Related Terms

Alpha Tau Medical Research & Development Historical Data

* Premium members only.

The historical data trend for Alpha Tau Medical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alpha Tau Medical Research & Development Chart

Alpha Tau Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 11.45 20.89 26.42 27.02 32.07

Alpha Tau Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.17 7.01 8.31 9.58 10.98
DRTS
32GF Score
Alpha Tau Medical Ltd DRTS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alpha Tau Medical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $35.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $35.87 Mil mean?
Alpha Tau Medical (DRTS) has a Research & Development of $35.87 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alpha Tau Medical and its competitors.
Is Alpha Tau Medical's Research & Development too high?
Alpha Tau Medical's current Research & Development is $35.87 Mil. Overall, Alpha Tau Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Research & Development compare to ORIC and OLMA?
Alpha Tau Medical's Research & Development of $35.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current Research & Development is $35.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Research & Development of $35.87 Mil. The current Research & Development is $35.87 Mil. Alpha Tau Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Research & Development is $35.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alpha Tau Medical Business Description

Address Kiryat HaMada Street 5, Jerusalem, ISR, 9777605
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
32GF Score

Get the complete analysis for DRTS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.22
Price